Lilly Zyprexa (correction)
Executive Summary
Lilly received an "approvable" letter from FDA on April 30 for its submission of two sNDAs for Zyprexa (olanzapine) for the treatment of schizophrenia and acute mixed or manic episodes associated with bipolar I disorder in adolescents, ages 13 to 17. A recent article in "The Pink Sheet" misstates the ages for proposed pediatric indications (1"The Pink Sheet" June 25, 2007, In Brief)...
You may also be interested in...
Risperdal, Zyprexa “approvable’ for teen schizophrenia
FDA issues an "approvable" letter June 21 to Johnson & Johnson unit Janssen for Risperdal (risperidone) to treat schizophrenia in children ages 13-17. A potential competitor in the space, Lilly's Zyprexa (olanzapine), is also approvable for an identical indication. Lilly told "The Pink Sheet" it received an approvable letter April 30 for Zyprexa to treat teen schizophrenia and acute mania associated with bipolar I disorder in children ages 10-17 years. FDA did not request any new clinical trials for either drug, according to the firms. The sNDAs for both drugs received "priority" review...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately-owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.